Kiniksa stock holds firm after a $243.6 million quarter

Kiniksa stock drew fresh attention after second-quarter revenue reached $243.6 million on July 28, 2026, while EPS came in at $0.30 and matched estimates.

Kiniksa Pharmaceuticals International, plc (US49704K1025) reported $243.6 million in revenue for the quarter ended July 28, 2026, and earned $0.30 per share, matching consensus. The company also posted a 9.59% net margin and 13.65% return on equity in the same update. MarketBeat consensus note

Revenue and earnings details

The quarter's revenue was above the $226.49 million consensus estimate, a gap of $17.11 million. Analysts now expect $1.37 in EPS for the current fiscal year, which gives the stock a clean comparison point after the reported $0.30 quarterly result.

That mix matters because Kiniksa's current narrative is still centered on execution rather than headline surprises. The latest figures show a profitable quarter with double-digit margins, and the revenue beat leaves the market focused on how durable that growth remains into the next reporting cycle.

Market view

The share count was carried by a market cap of $6.09 billion on August 31, 2026, while the same coverage snapshot described the stock as a consensus Moderate Buy. A second valuation anchor from a market-cap tracker put Kiniksa at $2.38 billion, showing how much market data can differ across vendors and publication methods on a single day.

For investors, the useful comparison is simple: the reported $243.6 million quarter and $0.30 EPS sit next to a $1.37 full-year EPS expectation, which keeps forward execution in the foreground. The stock's current size and the latest earnings beat matter more than broad biotech sentiment.

Investor focus

ARCALYST remains the company’s key commercial product and the main product-level reference point for the business, which makes prescription demand and repeat usage the metric to watch.

What the stock is worth

Kiniksa Pharmaceuticals stock trades on Nasdaq in USD. The market-cap snapshot showed $6.09 billion on August 31, 2026, and the latest earnings report gave investors $243.6 million of quarterly revenue to anchor the valuation discussion.

Fact box

Company: Kiniksa Pharmaceuticals International, plc
ISIN: US49704K1025
Ticker: KNSA
Exchange: Nasdaq
Sector / Industry: Health Care / Biotechnology
Index membership: Russell 2000